Benitec Biopharma Reports Director/Officer Changes & More

Ticker: BNTC · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1808898

Benitec Biopharma INC. 8-K Filing Summary
FieldDetail
CompanyBenitec Biopharma INC. (BNTC)
Form Type8-K
Filed DateNov 3, 2025
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.0001 B, $450,000 b
Sentimentneutral

Sentiment: neutral

Topics: management-change, corporate-governance, filing

TL;DR

Benitec Biopharma filed an 8-K detailing leadership changes and other corporate events.

AI Summary

Benitec Biopharma Inc. filed an 8-K on November 3, 2025, reporting events as of November 2, 2025. The filing indicates changes related to directors and officers, including elections and appointments, as well as compensatory arrangements. It also covers Regulation FD disclosures and other events, along with financial statements and exhibits.

Why It Matters

This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in directors and officers can indicate internal shifts that may affect company strategy and performance.

Key Numbers

Key Players & Entities

FAQ

What specific changes were made regarding directors or officers?

The filing indicates 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' suggesting changes in personnel at the leadership level, though specific names and details are not provided in this summary.

What is the significance of the 'Regulation FD Disclosure' item?

This indicates that the company is making public disclosures to prevent selective disclosure of material non-public information, ensuring fair access to information for all investors.

What types of financial statements and exhibits are included?

The filing notes 'Financial Statements and Exhibits' as an item, implying that financial reports and supporting documents are part of this submission, though their specific content is not detailed here.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this filing was on November 02, 2025.

What is Benitec Biopharma Inc.'s primary business sector?

Benitec Biopharma Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.

Filing Stats: 1,097 words · 4 min read · ~4 pages · Grade level 9.8 · Accepted 2025-11-03 07:11:20

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 3, 2025, Company issued a press release announcing that the FDA granted Fast Track Designation to BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy ("OPMD"), a chronic, life-threatening genetic disorder. In addition, the press release announced that the Company would host a live webcast of the Company's latest interim clinical data presentation at 8:00 am (Eastern Time) on November 3, 2025. A copy of this press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein to this Item 7.01. A copy of the presentation to be made in the webcast is attached hereto as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated by reference herein to this Item 7.01. The information included in this Current Report on Form 8-K (including Exhibits 99.2 and 99.3 hereto) that is furnished pursuant to this Item 7.01 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibits 99.2 and 99.3 hereto) that is furnished pursuant to this Item 7.01 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

01 Other Events

Item 8.01 Other Events. On November 3, 2025, the Company announced that the FDA granted Fast Track Designation to BB-301 for the treatment of OPMD, a chronic, life-threatening genetic disorder.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No . Description 99.1 Press Release of Benitec Biopharma Inc. (Board Appointment) dated November 3, 2025 99.2 Press Release of Benitec Biopharma Inc. (Fast Track Designation) dated November 3, 2025 99.3 Presentation of Benitec Biopharma Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BENITEC BIOPHARMA INC. Date: November 3, 2025 By: /s/ Dr. Jerel A. Banks Dr. Jerel A. Banks Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing